298 related articles for article (PubMed ID: 18311489)
1. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
4. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
5. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Uenaka A; Wada H; Isobe M; Saika T; Tsuji K; Sato E; Sato S; Noguchi Y; Kawabata R; Yasuda T; Doki Y; Kumon H; Iwatsuki K; Shiku H; Monden M; Jungbluth AA; Ritter G; Murphy R; Hoffman E; Old LJ; Nakayama E
Cancer Immun; 2007 Apr; 7():9. PubMed ID: 17441676
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
7. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
8. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
9. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
10. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
[TBL] [Abstract][Full Text] [Related]
12. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
13. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
14. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
[TBL] [Abstract][Full Text] [Related]
15. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
17. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma.
Saito T; Dworacki G; Gooding W; Lotze MT; Whiteside TL
Clin Cancer Res; 2000 Apr; 6(4):1351-64. PubMed ID: 10778963
[TBL] [Abstract][Full Text] [Related]
19. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
20. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
Wada H; Sato E; Uenaka A; Isobe M; Kawabata R; Nakamura Y; Iwae S; Yonezawa K; Yamasaki M; Miyata H; Doki Y; Shiku H; Jungbluth AA; Ritter G; Murphy R; Hoffman EW; Old LJ; Monden M; Nakayama E
Int J Cancer; 2008 Nov; 123(10):2362-9. PubMed ID: 18729190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]